Anti-TNF pharmacogenetic studies, including the different anti-TNF drugs infliximab (IFX), adalimumab (ADA) and etanercept (ETN), have so far been performed in RA, inflammatory bowel disease (IBD), PA and ankylosing spondylitis (AS) patients. Here, TNF is linked to rheumatoid arthritis.